Patient | Age | Sex | CD4+ cells/mm3 | Length of infection a | Antiviral drug | Clinical Evaluation b |
---|---|---|---|---|---|---|
MB | 28 yr | Â | 509 | 11 mo | None | Asymptomatic |
IB | 4.75 mo | M | 1942 | 4.75 mo | None | Asymptomatic, P1A |
MC | 23 yr | Â | 818 | 1 yr6 mo | None | Asymptomatic |
IC | 14 mo | F | 772 | 14 mo | ZDV | Symptomatic AIDS;P2A,D1,3,F |
MD | 31 yr | Â | 480 | 2 yr6 mo | None | Asymptomatic |
ID | 28 mo | M | 46 | 28 mo | ddCc | Symptomatic AIDS, P2AB,F; failed ZDV therapy |
MF | 23 yr | Â | 692 | 2 yr10 mo | None | Asymptomatic |
IF | 1 wk | M | 2953 | 1 wk | ZDV | Asymptomatic,P1A |
MH | 33 yr | Â | 538 | 5 mo | None | Asymptomatic |
IHT1 | 7 mo | F | 3157 | 7 mo | ACTG152 | Hepatosplenomeglay lymphadenopathy |
IHT2 | 7 mo | F | 2176 | 7 mo | ACTG152 | Hepatosplenomegaly lymphadenopathy |